{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007636","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.949258+00:00","generated_at":"2026-06-18T04:29:57.556539+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ovid Therapeutics reports FY2022 net loss $54.2M; cash $129M; pipeline advancing","bullets":["Net loss for FY2022 $54.2M ($0.77 per share) vs net income $122.8M ($1.78) in 2021, driven by prior Takeda milestone.","Cash and equivalents $129.0M; expected to fund operations into first half of 2025.","OV329 Phase 1 trial on track; full data with biomarker efficacy proxy expected H1 2024.","Takeda reaffirms soticlestat regulatory filings in FY2024; Ovid eligible for up to $660M milestones plus royalties.","Added epileptologist Manoj Malhotra and co-inventor Toshiya Nishi to leadership in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007636","json":"https://secwatch.observer/filing/0001628280-23-007636.json","markdown":"https://secwatch.observer/filing/0001628280-23-007636.md","text":"https://secwatch.observer/filing/0001628280-23-007636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/0001628280-23-007636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/ovid-20230313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:29:57.556539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"661f26e7cd16ffdcef72d3725ddc37ba0fe4d1f1","claim":"Ovid Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $46,280 for the fourth quarter and $1.5 million for the year ended December 31, 2022.","evidence_excerpt":"Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/0001628280-23-007636-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$46,280 for the fourth quarter and $1.5 million for the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}